Selank

Selank (Tuftsin analogue) is a heptapeptide. The HEIVE catalog describes it as: An anxiolytic peptide developed alongside Semax, studied for generalised anxiety without sedation.

HEIVE groups Selank under anxiety, stress, emotional balance, sleep and low mood. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for Selank under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval. Separately, Peptogen publishes Russian registration certificates for Selank 0.15% nasal drops. This does not validate injectable research products.

• FDA product data (October 6, 2026)
• FDA compounding safety information
• Manufacturer Selank registration certificates

The HEIVE editorial risk summary for Selank lists: Some users report flatness rather than calm. Longer-term concerns: No dependency observed in the Russian clinical record. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Selank has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Selank: 300 mcg subcutaneous, daytime. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Selank as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists a nasal form for Selank. A listed form is not evidence of an approved or effective treatment. Nasal forms are listed in the source catalog; this does not establish approval, efficacy or equivalent absorption. HEIVE injection calculations do not apply to nasal forms.

Preparation of Selank depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Selank depends on the specific formulation (injectable and nasal in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Selank: No tolerance described across 14-day courses. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Selank and Semax share the catalog categories focus, memory and mental clarity. Selank: An anxiolytic peptide developed alongside Semax, studied for generalised anxiety without sedation. Semax: A Russian-registered nootropic used clinically for stroke recovery; raises BDNF in animal and some human work. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Semax

The HEIVE editorial summary highlights: Immune markers shifted in trials that were only measuring anxiety scores. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.